In combination with dietary modifications, atorvastatin is FDA approved to prevent cardiovascular events in patients with cardiac risk factors and also patients with abnormal lipid profiles.

**Primary Prevention**

For patients without coronary heart disease but with multiple risk factors, the FDA has approved atorvastatin to reduce the risk of myocardial infarction, stroke, revascularization procedures, and angina.

For patients diagnosed with type 2 diabetes mellitus without coronary heart disease but with multiple risk factors, atorvastatin has FDA approval to reduce the risk of myocardial infarction and stroke.

**Secondary Prevention**

For patients with coronary heart disease, atorvastatin has received approval as a therapy to reduce the risk of nonfatal myocardial infarction, fatal and nonfatal stroke, revascularization procedures, hospitalizations for congestive heart failure, and angina.

Atorvastatin has FDA approval for the treatment of the following dyslipidemias:

- Adults with primary hyperlipidemia (heterozygous familial and nonfamilial) and mixed dyslipidemia

- Hypertriglyceridemia

- Primary dysbetalipoproteinemia

- Homozygous familial hypercholesterolemia

- Pediatric patients with heterozygous familial hypercholesterolemia (after failing dietary modifications)

Atorvastatin has not been studied in Fredrickson Type I and V dyslipidemias.